Basic researches and clinical practices of other tumor types have revealed that anti-angiogenic therapy such as anti-VEGF and multi-targeted small molecule anti- angiogenesis drugs can synergistically enhance the efficacy of immunotherapy by modulating tumor microenvironment, while little is reported on their combined use in MPM. The gene discussed is VEGFA; the disease is neoplasm.